Published in Cancer Gene Ther on September 13, 2013
Viral Therapy in Treating Patient With Liver Cancer | NCT01628640
Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses. Front Oncol (2014) 0.93
Complex Dynamics of Virus Spread from Low Infection Multiplicities: Implications for the Spread of Oncolytic Viruses. PLoS Comput Biol (2017) 0.91
Inhibitors of the interferon response enhance virus replication in vitro. PLoS One (2014) 0.84
Faster replication and higher expression levels of viral glycoproteins give the vesicular stomatitis virus/measles virus hybrid VSV-FH a growth advantage over measles virus. J Virol (2014) 0.80
Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1. Virology (2015) 0.79
STAT1 and NF-κB Inhibitors Diminish Basal Interferon-Stimulated Gene Expression and Improve the Productive Infection of Oncolytic HSV in MPNST Cells. Mol Cancer Res (2016) 0.78
Recombinant mumps virus as a cancer therapeutic agent. Mol Ther Oncolytics (2016) 0.75
Oncolytic virotherapy for head and neck cancer: current research and future developments. Oncolytic Virother (2015) 0.75
Interferon alpha bioactivity critically depends on Scavenger receptor class B type I function. Oncoimmunology (2016) 0.75
Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy. Mol Ther Oncolytics (2016) 0.75
Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis. J Virol (2015) 0.75
How cells respond to interferons. Annu Rev Biochem (1998) 24.27
A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature (1994) 11.50
Interferon-inducible antiviral effectors. Nat Rev Immunol (2008) 9.68
Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol (2001) 6.19
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell (2003) 5.89
Oncolytic virotherapy. Nat Biotechnol (2012) 5.79
Histone deacetylase inhibitors in cancer therapy. J Clin Oncol (2009) 4.58
Complex modulation of cell type-specific signaling in response to type I interferons. Immunity (2006) 4.48
Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol (2011) 4.06
Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway. Nat Immunol (2008) 3.43
Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol (1999) 3.04
Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J Exp Med (2006) 2.83
Comparative analysis of IRF and IFN-alpha expression in human plasmacytoid and monocyte-derived dendritic cells. J Leukoc Biol (2003) 2.61
Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res (2011) 2.54
Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg Med Chem Lett (2002) 2.21
Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J Virol (2003) 2.10
Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc Natl Acad Sci U S A (2004) 2.04
LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proc Natl Acad Sci U S A (2013) 1.75
Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc Natl Acad Sci U S A (2008) 1.73
STAT3 complements defects in an interferon-resistant cell line: evidence for an essential role for STAT3 in interferon signaling and biological activities. Proc Natl Acad Sci U S A (1998) 1.64
Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert Opin Biol Ther (2009) 1.54
Vesicular stomatitis virus infection of the central nervous system activates both innate and acquired immunity. J Virol (1995) 1.52
The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. Clin Cancer Res (2006) 1.50
Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting. J Virol (2009) 1.46
Characterization of nonpathogenic, live, viral vaccine vectors inducing potent cellular immune responses. J Virol (2004) 1.46
Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Proc Natl Acad Sci U S A (2010) 1.39
Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clin Cancer Res (2012) 1.35
Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. J Gen Virol (2012) 1.34
Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β. Cancer Gene Ther (2012) 1.24
Emergence and re-emergence of vesicular stomatitis in the United States. Virus Res (2002) 1.19
Reengineering paramyxovirus tropism. Virology (2004) 1.18
Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates. Hum Gene Ther (2010) 1.18
Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib. Curr Med Chem (2012) 1.16
Immune response in the absence of neurovirulence in mice infected with m protein mutant vesicular stomatitis virus. J Virol (2008) 1.13
Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Curr Opin Pharmacol (2012) 1.12
Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector. Springer Semin Immunopathol (2006) 1.12
Oxidative stress inhibits IFN-alpha-induced antiviral gene expression by blocking the JAK-STAT pathway. J Hepatol (2006) 1.12
Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling. Virology (2012) 1.12
Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis. Expert Opin Pharmacother (2012) 1.06
Early steps of the virus replication cycle are inhibited in prostate cancer cells resistant to oncolytic vesicular stomatitis virus. J Virol (2008) 1.05
Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways. J Virol (2011) 1.04
Novel high-throughput screening system for identifying STAT3-SH2 antagonists. Biochem Biophys Res Commun (2009) 1.02
p37δ is a new isoform of PI3K p110δ that increases cell proliferation and is overexpressed in tumors. Oncogene (2011) 0.91
Neuroattenuation of vesicular stomatitis virus through picornaviral internal ribosome entry sites. J Virol (2013) 0.89
Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition. Mol Oncol (2012) 0.89
JAK2 inhibitors and their impact in myeloproliferative neoplasms. Hematology (2012) 0.81
Evaluation of innate immune signaling pathways in transformed cells. Methods Mol Biol (2012) 0.78
A possible correlation between interferon-stimulated gene expression and cytogenetic responses in chronic myelogenous leukemia patients treated with alpha-interferon. Jpn J Clin Oncol (1996) 0.77
Lesion development and replication kinetics during early infection in cattle inoculated with Vesicular stomatitis New Jersey virus via scarification and black fly (Simulium vittatum) bite. Vet Pathol (2010) 0.76
Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J Mol Biol (1992) 2.50
Retroviral retargeting by envelopes expressing an N-terminal binding domain. J Virol (1995) 2.36
Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int (2008) 2.21
Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet (1986) 2.04
A proline-rich motif downstream of the receptor binding domain modulates conformation and fusogenicity of murine retroviral envelopes. J Virol (1998) 1.89
Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood (2001) 1.84
Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood (2001) 1.82
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia (2010) 1.77
Activation of a cell entry pathway common to type C mammalian retroviruses by soluble envelope fragments. J Virol (2000) 1.72
Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther (2007) 1.67
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia (2007) 1.66
Long-term outcomes in children with high-risk neuroblastoma treated with autologous stem cell transplantation. Bone Marrow Transplant (2007) 1.56
Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest (1994) 1.54
The epidemiology of dog walking: an unmet need for human and canine health. Med J Aust (2002) 1.53
Systematic administration of B vitamins attenuates neuropathic hyperalgesia and reduces spinal neuron injury following temporary spinal cord ischaemia in rats. Eur J Pain (2013) 1.47
Recombinant measles viruses efficiently entering cells through targeted receptors. J Virol (2000) 1.44
Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Ther (2010) 1.44
Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther (2006) 1.43
Gastric cancer exosomes promote tumour cell proliferation through PI3K/Akt and MAPK/ERK activation. Dig Liver Dis (2009) 1.39
The 19S complex of the proteasome regulates nucleotide excision repair in yeast. Genes Dev (2001) 1.36
Polyploidy, phylogeography and Pleistocene refugia of the rockfern Asplenium ceterach: evidence from chloroplast DNA. Mol Ecol (2002) 1.36
Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. J Virol (2001) 1.31
Improvement of retroviral retargeting by using amino acid spacers between an additional binding domain and the N terminus of Moloney murine leukemia virus SU. J Virol (1996) 1.30
Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth. Cancer Res (2000) 1.24
Discovery of antibodies. BMJ (1992) 1.24
Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β. Cancer Gene Ther (2012) 1.24
Retargeting gene delivery using surface-engineered retroviral vector particles. Curr Opin Biotechnol (2001) 1.20
Curative one-shot systemic virotherapy in murine myeloma. Leukemia (2012) 1.20
Targeting retrovirus entry. Gene Ther (1996) 1.19
Targeting retroviral and lentiviral vectors. Curr Top Microbiol Immunol (2003) 1.19
Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth. Gene Ther (2008) 1.18
Glycoprotein folding in the endoplasmic reticulum: a tale of three chaperones? FEBS Lett (2000) 1.15
Targeting of retroviral vectors through protease-substrate interactions. Gene Ther (1996) 1.15
Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses. Gene Ther (2012) 1.12
Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. Hum Gene Ther (2001) 1.07
Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model. Cancer Gene Ther (2006) 1.07
Receptor co-operation in retrovirus entry: recruitment of an auxiliary entry mechanism after retargeted binding. EMBO J (1997) 1.07
Goats' milk quackery. J Paediatr Child Health (2005) 1.07
Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices. Gene Ther (2002) 1.05
Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors. Crit Rev Oncol Hematol (2001) 1.04
Organ distribution of gene expression after intravenous infusion of targeted and untargeted lentiviral vectors. Gene Ther (2001) 1.04
Prestin up-regulation in chronic salicylate (aspirin) administration: an implication of functional dependence of prestin expression. Cell Mol Life Sci (2008) 1.04
Retroviral display of antibody fragments; interdomain spacing strongly influences vector infectivity. Hum Gene Ther (1996) 1.03
Incorporation of fowl plague virus hemagglutinin into murine leukemia virus particles and analysis of the infectivity of the pseudotyped retroviruses. J Virol (1998) 1.03
Genetic discontinuity, breeding-system change and population history of Arabis alpina in the Italian Peninsula and adjacent Alps. Mol Ecol (2008) 1.02
Cancer gene therapy: hard lessons and new courses. Gene Ther (2000) 1.01
Generation and characterization of recombinant human antibodies specific for native laminin epitopes: potential application in cancer therapy. Cancer Immunol Immunother (2001) 0.99
A hyperfusogenic gibbon ape leukemia envelope glycoprotein: targeting of a cytotoxic gene by ligand display. Hum Gene Ther (2000) 0.99
Measles virus as an oncolytic vector platform. Curr Gene Ther (2008) 0.98
The contribution of contact and non-contact residues of antibody in the affinity of binding to antigen. The interaction of mutant D1.3 antibodies with lysozyme. J Mol Biol (1993) 0.98
Retroviral display of functional binding domains fused to the amino terminus of influenza hemagglutinin. Hum Gene Ther (1999) 0.97
In vivo selection of protease cleavage sites from retrovirus display libraries. Nat Biotechnol (1998) 0.97
Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus. Gene Ther (2005) 0.97
Pinhole micro-SPECT/CT for noninvasive monitoring and quantitation of oncolytic virus dispersion and percent infection in solid tumors. Gene Ther (2011) 0.95
Mitochondrial DNA sequence diversity and origin of Chinese domestic yak. Anim Genet (2007) 0.93
Amiodarone induced skin necrosis. Heart (2006) 0.93
Dynamics of multiple myeloma tumor therapy with a recombinant measles virus. Cancer Gene Ther (2009) 0.93
Genetic diversity and phylogeography in two diploid ferns, Asplenium fontanum subsp. fontanum and A. petrarchae subsp. bivalens, in the western Mediterranean. Mol Ecol (2009) 0.92
Efficient discrimination between different densities of target antigen by tetracycline-regulatable T bodies. Hum Gene Ther (1999) 0.91
Recombination diversifies chloroplast trnF pseudogenes in Arabidopsis lyrata. J Evol Biol (2007) 0.91
Retroviruses as vectors. Br Med Bull (1995) 0.91
Inverse targeting of retroviral vectors: selective gene transfer in a mixed population of hematopoietic and nonhematopoietic cells. Blood (1998) 0.90
Pharmacologic suppression of target cell recognition by engineered T cells expressing chimeric T-cell receptors. Cancer Gene Ther (2000) 0.89
Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy. Cancer Gene Ther (2012) 0.88
Are GPs using clinical practice guidelines? Aust Fam Physician (2001) 0.88
Heroin abuse accelerates biological aging: a novel insight from telomerase and brain imaging interaction. Transl Psychiatry (2013) 0.87
Tissue-specific gene expression from Mo-MLV retroviral vectors with hybrid LTRs containing the murine tyrosinase enhancer/promoter. Virology (1995) 0.86
RUNX3-mediated transcriptional inhibition of Akt suppresses tumorigenesis of human gastric cancer cells. Oncogene (2012) 0.86
Directed evolution of retroviruses activatable by tumour-associated matrix metalloproteases. Gene Ther (2003) 0.86
Diagnosis and surgical treatment of carotid body tumors: 25 years' experience in China. Int J Oral Maxillofac Surg (2009) 0.86
HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy. Cancer Gene Ther (2013) 0.86
Viral vector targeting. Curr Opin Biotechnol (1999) 0.85
A gene delivery system activatable by disease-associated matrix metalloproteinases. Hum Gene Ther (1997) 0.85
Complement depletion does not reduce brain injury in a rabbit model of thromboembolic stroke. Brain Res Bull (1999) 0.85
Targeting virus entry and membrane fusion through specific peptide/MHC complexes using a high-affinity T-cell receptor. Gene Ther (2004) 0.84
Gene transfer technologies for the gene therapy of cancer. Gene Ther (1994) 0.84
Modification of retroviral tropism by display of IGF-I. J Mol Biol (1999) 0.84
Randomised controlled trial comparing the effect of brimonidine and timolol on visual field loss after acute primary angle closure. Br J Ophthalmol (2004) 0.84
The innovative evolution of cancer gene and cellular therapies. Cancer Gene Ther (2013) 0.83
Involvement of nuclear factor κB (NF-κB) in the downregulation of cyclooxygenase-2 (COX-2) by genistein in gastric cancer cells. J Int Med Res (2011) 0.83
Concentration of viral vectors by co-precipitation with calcium phosphate. J Gene Med (2001) 0.83
Heat shock protein inhibitors increase the efficacy of measles virotherapy. Gene Ther (2008) 0.83
A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy. Gene Ther (2000) 0.83
Y-box binding protein 1 expression in gastric cancer subtypes and association with cancer neovasculature. Clin Transl Oncol (2014) 0.83
Population structure and historical biogeography of European Arabidopsis lyrata. Heredity (Edinb) (2010) 0.82
Library-based selection of retroviruses selectively spreading through matrix metalloprotease-positive cells. Gene Ther (2005) 0.82
Polyinosinic acid decreases sequestration and improves systemic therapy of measles virus. Cancer Gene Ther (2011) 0.82
Use of teicoplanin for Hickman catheter associated staphylococcal infection in immunosuppressed patients. J Hosp Infect (1987) 0.81
Dexamethasone and the risk for adrenal suppression in multiple myeloma. Leukemia (2009) 0.81
Enhanced transduction efficiency of retroviral vectors coprecipitated with calcium phosphate. Gene Ther (1995) 0.81
A unique haplotype of the apolipoprotein B-100 allele associated with familial defective apolipoprotein B-100 in a Chinese man discovered during a study of the prevalence of this disorder. J Lipid Res (1993) 0.81
A genetic approach to idiotypic vaccination. J Immunother Emphasis Tumor Immunol (1993) 0.81